Vista Partners Initiates Coverage on Pro-Pharmaceuticals, Inc.; $1.95 Target Price

LOS ANGELES, Feb. 3 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Pro-Pharmaceuticals, Inc. (OTC Bulletin Board: PRWP) with a twelve month target price of $1.95. Ross Silver, CEO & Principal Analyst at Vista Partners stated, "We believe Pro-Pharmaceutical's lead compound, DAVANAT®, will revolutionize oncology. DAVANAT® has shown in late stage clinical trials that it can significantly increase the uptake of chemotherapeutics into a tumor and significantly reduce Severe Adverse Events (SAE's) caused by chemotherapy. This is noteworthy considering the size of the oncology market is in the billions and the size of the market to treat side effects of already approved oncology drugs is also in the billions. DAVANAT® could potentially enhance the efficacy of already approved oncology drugs while also reducing the side effect profile of these drugs. By doing so, patients potentially will live longer and live better." To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please click on this link.

About Vista Partners:

With offices in California and Oregon, Vista Partners LLC is one of the fastest growing independently owned equity research and consulting firms in the United States. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment recommendations.

SOURCE Vista Partners

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED